Cancer BiologybioRxivPreprint
Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer
B. R. Corr, M. R. Moroney, E. R. Woodruff…·B. G. Bitler
This paper evaluates SM08502, a CLK/DYRK inhibitor, as a single-agent and in combination with paclitaxel for CTNNB1-mutated endometrial cancer, showing synergistic effects and tumor volume reduction in vitro and in vivo.
DOI 10.1101/2023.04.04.535570